Precision Biosciences (DTIL) Common Equity (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Common Equity data on file, last reported at $76.1 million in Q1 2026.

• On a quarterly basis, Common Equity rose 54.25% year-over-year to $76.1 million in Q1 2026; TTM through Mar 2026 was $76.1 million, a 54.25% increase from a year earlier, with the FY2025 full-year figure at $92.2 million, up 63.58% from the prior year.
• Common Equity for Q1 2026 stood at $76.1 million, down from $92.2 million in the prior quarter.
• Over the last five years, Common Equity for DTIL reached as high as $103.0 million in Q2 2022 and fell as low as $16.6 million in Q3 2025.
• Historically, Common Equity has averaged $55.4 million across 5 years, with a median of $56.4 million in 2024.
• Across the five-year window, Common Equity surged 198.99% in 2024 and sank 74.36% in 2025, its largest moves.
• Year by year, Common Equity stood at $60.4 million in 2022, then slumped by 68.79% to $18.9 million in 2023, then jumped by 198.99% to $56.4 million in 2024, then soared by 63.58% to $92.2 million in 2025, then dropped by 17.5% to $76.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $76.1 million in Q1 2026, $92.2 million in Q4 2025, and $16.6 million in Q3 2025.